Cirriculum Vitae

1. Name Surname : Veysel Sabri Hançer
2. Date of Birth : 31.05.1978
3. Title : Prof.Dr.
4. State of Education : Doctorate
5. Current Institution : Istinye University

Degree	Department	University	Date
B.Sc	Molecular Biology / Faculty of science	Ege University	1999
M.Sc	Molecular Biology/ Institute of science	Ege University	2001
Ph.D	Molecular Biology and Genetics/ Institute of science	Istanbul University	2009

5.1. Academic Appointments

Assistant Proffessor: March 2010

Associate Professor: March 2013

Professor : May 2018

5.2. Professional Experience

Istanbul Faculty of Medicine, Head of the Molecular Hematology Laboratory 2000-2010

Florence Nightingale Hospital, Genetic Diagnostic Center, Head of the Molecular Genetics Laboratories 2010-2016

Istinye University, Genetic Diagnostic Center, Head of the Molecular Genetics Laboratories 2016-Present

Assistant Professor : Istanbul Bilim University, Faculty of Medicine, Department of Medical Biology and Genetics 2010-2013

Associate Professor : Istanbul Bilim University, Faculty of Medicine, Department of Medical Biology and Genetics 2013-2016

Associate Professor : Istinye University, Faculty of Medicine, Department of Medical Genetics 2016- 2018

Professor: Istinye University, Faculty of Medicine, Department of Biology 2018-

6. Thesis Advised

6.1. Postgraduate Thesis

6.1.1. Transcription analysis of activation-induced cytidine deaminase (AID) gene in antiphospholipid syndrome. Istanbul Bilim University. (Tuğba Varlık, 2011).

6.1.2. Detection of BRCA1185delAG, 5382insC ve BRCA2 6174delT and V2466A mutations with multiplex PCR in a single step. (Merve Tecer, 2013).

6.1.3. Analysis of MRP-1 and MRP-2 gene expressions in Dilated cardiomyopathy patients. (Şeyda Ercan, 2015)

7. Publications

7.1. Articles Published in International refereed journals (SCI,SSCI)

7.1.1. Diz-Kucukkaya R, **Hancer VS**, Nalcaci M, Inanc M, Pekcelen Y. Factor XIII Val34Leu polymorphism does not contribute to the prevention of trombotic complication in patients with antiphospholipid syndrome. *Lupus* 2004;13: 32-35.

7.1.2. **Hancer VS**, Diz-Kucukkaya R, Nalcaci M. Turkish population data on the factor XIII Val34Leu, glycoprotein (GP)Ibα Kozak and P- selectin glycoprotein ligand 1 (PSGL-1) loci. *Cell Biochem Funct* 2005; 23: 55-82.

7.1.3. **Hancer VS**, Diz-Kucukkaya R, Bilge AK, Ozben B, Oncul A, Ergen G, Nalcaci M. The association between factor XIII Val34Leu polymorphism and early myocardial infarction.*Circ J* 2006; 70: 239-242.

7.1.4. Ozben B, Diz-Kucukkaya R, Bilge AK, **Hancer VS**, Oncul A. The association of P selectin glycoprotein ligand-1 VNTR polymorphisms with coronary stent restenosis. *J Thromb Thrombolysis* 2007; 23:181-187.

7.1.5. Ozben B, Altun I, **Hancer VS**, Bilge AK, Tanrikulu AM, Diz-Kucukkaya R, Fak AS, Yilmaz E, Adalet K. Angiotensin-converting enzyme gene polymorphism in arrhythmogenic right ventricular dysplasia: is DD genotype helpful in predicting syncop risk? *J Renin Angiotensin Aldosterone Syst* 2008; 9; 215-220.

7.1.6. Diz-Kucukkaya R, **Hancer VS**, Artim-Esen B, Pekcelen Y, Inanc M, The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. *J Thromb Thrombolysis* 2010; 29: 303-309.

7.1.7. Pamukcu B, Oflaz H, Onur I, **Hancer V**, Yavuz S, Nisanci Y. Impact of genetic polymorphisms on platelet function and aspirin resistance. *Blood Coagul Fibrinolysis* 2010; 21: 53-56.

7.1.8. Akturk F, **Hancer VS**, Kucukkaya R. Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) A49G Polymorphism and Autoimmune Blood Diseases. *Turk J Hematol* 2010; 27: 78-81.

7.1.9. Hancer VS, Kose M, Diz-Kucukkaya R ,Yavuz AK, Aktan M, Activation- induced cytidine deaminase mRNA levels in chronic lymphocytic leukemia. *Leuk Lymph* 2011; 52: 79-84.

7.1.10. Topal NP, Ozben B, **Hancer VS**, Tanrikulu AM, Diz-Kucukkaya R, Fak AS, Basaran Y, Yesildag O. Polymorphisms of the angiotensin-converting enzyme and angiotensinogen gene in patients with atrial fibrillation. *J Renin Angiotensin Aldosterone Syst* 2011; 12: 549-556.

7.1.11. Hancer VS, Buyukdogan M, Turkmen I, Bassullu N, Altug T, Diz-Kucukkaya R, Bulbul-Dogusoy G, Demir G. Comparison of KRAS Mutation Tests in Colorectal Cancer Patients. *Genet Test Mol Biomarkers* 2011; 15: 831-834.

7.1.12. Hancer VS, Diz-Kucukkaya R, Topal-Sarikaya A. ADAMTS-13 gene expression in antiphospholipid syndrome. *Turk J Hematol* 2011; 28: 213-218.

7.1.13. Hancer VS, Diz-Kucukkaya R, Aktan M. Overexpression of Fc Mu Receptor (FCMR,TOSO) Gene In Chronic Lymphocytic Leukemia Patients. *Med Oncol*, 2012; 29: 1068-1072.

7.1.14. Eskazan AE, Salihoglu A, Diz-Kucukkaya R, **Hancer VS**, Soysal T. Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm. *Ann Hematol* 2012; 91: 305-306.

7.1.15. Yonal I, Hindilerden F, **Hancer VS**, Artim-Esen B, Daglar A, Akadam B, Nalcaci M, Diz-Kucukkaya R. The impact of platelet membrane glycoprotein Ib alpha and Ia/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome. *Thromb Res* 2012; 129: 486-491.

7.1.16. Esen FI, **Hancer VS**, Küçükkaya RD, Yeşilot N, Coban O, Bahar S, Tuncay R. Glycoprotein Ib-alpha Kozak polymorphism in ischemic stroke. *Neurol Res* 2012; 34: 68-71.

7.1.17. Yonal I, Pinarbası B, Hindilerden F, **Hancer VS**, Nalcaci M, Kaymakoglu S, Diz-Kucukkaya R. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. *Thromb Thrombolysis* 2012; 34: 388-396.

7.1.18. Cayci FS, Cakar N, **Hancer VS**, Uncu N, Acar B, Gur G. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. *Pediatr Nephrol* 2012; 27: 2327-2331.

7.1.19. Gulleroglu K, Fidan K, **Hançer VS**, Bayrakci U, Baskin E, Soylemezoglu O. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. *Pediatr Nephrol* 2013; 28: 827-830.

7.1.20. Akpinar TS, **Hancer VS**, Nalcaci M, Diz-Kucukkaya R. MPL W515L/K mutations in chronic myeloproliferative neoplasms. *Turk J Hematol* 2013; 30: 8-12.

7.1.21. Yalcin AA, Akturk IF, Celik O, Erturk M, Hancer VS, Yalcin B, Isıksacan N, Uzun F, Ozyılmaz SO, Bıyık I. Coronary artery ectasia is associated with the c.894G>T (Glu298Asp) polymorphism of the endothelial nitric oxide synthase gene. *Tohoku J Exp Med* 2014; 232: 137-144.

7.1.22. Alpay N, **Hançer VS**, Erer B, İnanç M, Diz-Küçükkaya R. The Relationship between P-Selectin Polymorphisms and Thrombosis in Antiphospholipid Syndrome: A Pilot Case- Control Study. *Turk J Haematol* 2014; 31: 357-362.

7.1.23. Ekinci Z, Bek K, Aytaç MB, Karadenizli A, **Hançer VS**. Renal outcome with eculizumab in two diarrhea-associated hemolytic-uremic syndrome cases with severe neurologic involvement. Hong Kong Journal of Nephrology 2014: 16: 46-49.

7.1.24. Gönenç G, Işçi H, Yiğiter AB, **Hançer V**, Büyükdoğan M, Güdücü N, Dünder I. Non-invasive prenatal diagnosis of fetal RhD by using free fetal DNA. *Clin Exp Obstet Gynecol*. 2015;42: 344-346.

7.1.25. Kasapoğlu U, Ruhi Ç, Tuğcu M, Boynueğri B, Titiz İ, **Hançer VS**, Apaydın S. Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome. *Ann Transplant*. 2015; 20:714-719.

7.1.26. Yavuz S, Akdeniz T, **Hancer V**, Can M, Yanıkkaya-Demirel G. Dual effects of testosterone in Behcet's disease: implications for a role in disease pathogenesis. *Genes Immun*. 2016; 17: 335-341.

7.1.27. Golcuk E, Yalin K, Akdeniz CS, Teker E, Teker B, Hancer VS, Altun I, Sezer M, Diz-Kucukkaya R, Oncul A. Glycoprotein Ibα Kozak polymorphism in patients presenting with early-onset acute coronary syndrome. *Arch Med Sci* 2016 DOI: 10.5114/aoms.2016.63278

7.1.28. Caglar FNT, Biyik I, Isiksacan N, **Hancer VS**, Akturk IF, Ciftci S, Ungan I, Sahin A, Uzun F. P-selectin glycoprotein ligand-1 variable number of tandem repeats polymorphism in young myocardial infarction patients. Arch Med Sci Civil Dis 2016;1: e112–e116.

7.1.29. Sengul EA, Artunay O, Rasier R, Kockar A, Afacan C, **Hancer VS**, Yuzbasioglu E. Pharmacogenetic Aspect of Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Five-Year Follow-Up. Ocul Immunol Inflamm 2017; 4:1-7.

7.1.30. Hancer VS, Tokgöz H, Guvenc S, Caliskan U, Buyukdogan M. Three novel calreticulin mutations in two Turkish patients. Turk J Haematol 2017;34: 360-361.

7.1.31. Hancer VS, Yarimcan FS, Buyukdogan M, Aki SZ, Oksuz B, Acar K, Acar M, Bulut P. A Novel Ganciclovir Resistance Mutation in the UL97 Gene of the HHV-5 in an Adult Hematopoietic Stem Cell Transplant Recipient. Future Virology 2017; 12: 761-766.

7.1.32. Hancer VS, Gokgoz Z, Buyukdogan M. Three Factor 11 mutations associated with Factor XI deficiency in a Turkish family. . Turk J Haematol 2018; 35: 79-80.

7.1.33. Hancer VS, Fisgin T, Buyukdogan M, Bozkurt C, Lako S. B globin mutations in Turkish, Northern Iraqi and Albanian patients with b thalassemia major. Thalassemia Reports 2018; 8: 97-100.

7.1.34. Hancer VS, Buyukdogan M, Bylykbashi I, Oksuz B, Acar M. Prevalence of human papilloma virus types in Turkish and Albanian women. J Cytol 2018; 35: 252-254.

7.1.35. Ibis K, Saglam S, Saglam EK, Firat P, Yilmazbayhan B, Toker A, Ozkan B, **Hancer VS**, Buyukdogan M, Disci R, Pilanci KN. Prognostic significance of carbonic anhydrase IX overexpression in stage III non-small cell lung cancer patients after neoadjuvant treatment. Pathology Research and Practice 2018; 214: 1291-1296.

7.1.36. Karacan İ, Diz Kucukkaya R, Karakus FN, Solakoglu S, Tolun A, **Hancer VS**, Turanli ET. A Novel ATP6V0A2 Mutation Causing Recessive Cutis Laxa with Unusual Manifestations of Bleeding Diathesis and Defective Wound Healing. Turk J Haematol 2019;36: 29-36.

7.2. Articles Published in International journals are not indexing with SCI

7.3. Proceedings

7.3.1. Diz-Kucukkaya R, **Hancer VS**, Inanc M, Nalcaci M, Pekcelen Y. Factor XIII Val34Leu polymorphism does not affect the risk for thrombotic complications in patients with antiphospholipid syndrome. *Blood* 2003; 102: 315A-315A.

7.3.2. Kaftancioglu U, Turgut E, **Hancer V**, Cesur V, Akgul N, Esen BA, Kalayoglu S, Sargin D. HLA Full Match Donors. *Bone Marrow Transplant* 2003; 31: S290.

7.3.3. Turgut E, Kaftancioglu U, Cesur V, Akgul N, Esen BA, **Hancer V**, Kalayoglu S, Sargin D. The effect of stem cell transplantation on social and economic status in a developing country on family basis. *Bone Marrow Transplant* 2003; 31: S296.

7.3.4. Akturk F, **Hancer VS**, Guvenc S, Artim-Esen B, Diz-Kucukkaya R. CTLA-4 A49G polymorphism and autoimmune blood diseases. 10th Congress of the European Hematology Association Abstract book 2005; s2.

7.3.5. Akturk F, **Hancer VS**, Guvenc S, Artim-Esen B, Diz-Kucukkaya R. CTLA-4 A49G polymorphism and autoimmune blood diseases. *Blood* 2006; 108: 48B-48B.

7.3.6. Sadic BO, Bilge AK, **Hancer VS**, Oncul A, Kucukkaya RD, Nalcaci M. The association between factor XIII Val34Leu polymorphism and early myocardial infarction. *Eur Heart J* 2006; 27: 76.

7.3.7. Akturk F, **Hancer VS**, Guvenc S, Diz-Kucukkaya R. The association between cytotoxic T lymphocyte antigen-4 (CTLA-4) A49G polymorphism and autoimmune blood diseases. *FEBS Journal* 2006; 273: 274.

7.3.8. Taranoglu O, **Hancer V**, Kalender M, Diz-Kucukkaya R, Inanc M. P-selectin glycoprotein ligand 1 VNTR polymorphisms in systemic sclerosis. *Blood* 2007; 110: 46B-47B.

7.3.9. Taranoglu O, **Hancer V**, Kalender M, Sadri S, Diz-Kucukkaya R, Inanc M. P-selectin glycoprotein ligand 1 VNTR polymorphisms in systemic sclerosis. *Arthritis Rheum* 2007; 56: 4305.

7.3.10. **Hancer VS**, Diz-Kucukkaya R, Topal-Sarikaya A. ADAMTS-13 Gene Mutations and Transcription Analysis in Primary Antiphospholipid Syndrome. *Blood* 2008; 112: 642.

7.3.11. Pamukcu B, Oflaz H, Onur I**, Hancer V**, Yavuz S, Adalet K, Bugra Z, Nisanci Y. Impact of genetic polymorphisms on platelet function and aspirin resistance. *Atherosclerosis* 2008; 9: 41.

7.3.12. Kahraman R, **Hançer V**, Diz-Küçükkaya R. Tissue factor -603A/G polymorphism and tissue factor levels in patients with antiphospholipid syndrome. *J Thromb Haemostasis* 2009; 7: PP-TH-270.

7.3.13. Yonal I, Hindilerden F, **Hancer VS**, Artim-Esen B, Nalcaci M, Diz-Kucukkaya R. Frequency and clinical outcomes of platelet membrane glycoprotein polymorphisms in antiphospholipid syndrome. 52nd American Society of Hematology Annual Meeting and Exposition program book 2010; 3171.

7.3.14. Esen FI, **Hancer VS**, Diz-Kucukkaya R, Yesilot N, Coban O. Platelet glycoprotein Ib-alpha Kozak polymorphism in ischemic stroke. *Cerebrovasc Dis* 2010; 29: 180.

7.3.15. Yonal I, Pinarbasi B, Hindilerden F, **Hancer VS**, Nalcaci M, Kaymakoglu S, Diz-Kucukkaya R. The clinical significance of JAK2 V617F mutation for Philedelphia-negative chronic myeloproliferative diseases in patients with splanchnic vein thrombosis. 16th Congress of the European Hematology Association abstract book 2011; 96(s2),73.

7.3.16. Dermenci H, Daglar A, Akadam BP, **Hancer VS**, Gelmez Y, Aktan M, Nalcaci M, Yavuz AS. Can Activation Induced Cytidine Deaminase Lead to Genetic Instability in Bcr-Abl Negative Myeloproliferative Neoplasms? Blood 2012; 120:5056.

7.3.17. Ermis E, Demirelli S, Ipek E, Ciftci C, **Hancer VS**, Poyraz E. Investigation of Arrhythmia Markers and KCNJ8-S422L Gene Mutation in a Population with Early Repolarization Pattern on ECG. Journal of the American College of Cardiology 2013; 62, C68.

7.3.18. Yalcin AA, Akturk IF, **Hancer VS**, Celik O, Uzun F, Erturk M, Sarikamis C, Ozyilmaz SO, Oner E, Birand A, Kalkan AK, Enhos A. Association Between Glu298Asp Polymorphism of the eNOS Gene and Coronary No-Reflow in Patients Undergoing Primary Percutenous Intervention. Journal of the American College of Cardiology 2013; 62, C238.

7.3.19. Yalcin AA, Ozyilmaz SO, Akturk IF, **Hancer VS**, Celik O, Uzun F, Erturk M, Birand A, Oner E, Kalkan AK. Is the Glu298Asp polymorphism of Endothelial Nitric Oxide Synthesis Increase the Risk of Stent Thrombosis? Journal of the American College of Cardiology 2013; 62, C231.

7.3.20. Bozkurt M, Okutur K, Aydın K, Namal E, Ozturk A, Planci KN, **Hancer VS**, Tecimer C, Kucukkaya R, Demir G. The impact of prothrombotic mutations, PSGL-1 VNTR polymorphism, tissue factor and soluble P-selectin on venous thromboembolism in cancer patients with adenocarcinoma. Journal of Clinical Oncology 2014; 32,e22049.

7.3.21. Gokgoz Z, **Hancer VS**, Kucukkaya R. Two Novel Mutations (p. I454T and p. Y472X) and a Homozygous p. A109T Mutation Associated with Factor XI Deficiency in a Turkish Family. Blood 2014; 124:5054.

7.3.22. **Hancer VS**, Guvenc S, Hindilerden F, Buyukdogan M, Kucukkaya R. Analysis of the complement pathway mutations in atypical hemolytic uremic syndrome (AHUS). Thrombosis Research 2014; 133, 81.

7.3.23. Tokgoz H, Caliskan U, Kucukkaya R, Demir A, **Hancer VS**. Two Pediatric Cases of Essential Thrombocytopenia Characterized By Extremely Rare Mutations. 57th American Society of Hematology meeting 2015; 126, 4662.

7.3.24. Guvenc S, **Hancer VS**, Uslu N, Arat M, Kucukkaya R. Two novel calreticulin mutations in a turkish patient with primary myelofibrosis: c.1116delA and c.1120A>C. 20th Congress of the European Hematology Association abstract book 2015; 102886.

7.3.25. Kasapoglu U, Caglar R, Tugcu M, Boynuegri B, Titiz I, **Hancer VS**, Apaydin S. A successful kidney transplantation with prophylactic eculizumab treatment in a patient with atypical hemolytic uremic syndrome. Transplant International 2015; 28, 641.

7.3.26. Turan C, Guvenc S, **Hancer VS**, Hindilerden F, Arat M, Kucukkaya R. TET2 mutations in essential thrombocytemia and primary myelofibrosis. Haematologica 2015; 100: 753.

7.3.27. Tokgoz H, Caliskan U, Kucukkaya R, **Hancer VS**. MPL W515K mutation in a pediatric case of essential thrombocythemia presenting with budd-chiari syndrome. Thrombosis Research 2016; 141, S75.

7.3.28. Saglam S, Ibis K, Saglam EK, Firat P, Yilmazbayhan D, Toker A, Ozkan B, **Hancer V**, Buyukdogan M, Disci R. Prognostic Significance of CA IX Overexpression in Stage III NSCLC Patients Received Neoadjuvant Treatment. Journal of Thorasic Oncology 2017; 12: S841.

7.4. International books published, or chapters from a book

7.5. Articles published in national refreed journals

7.6. Assertions presented in national scientific congresses and published in the proceedings.

7.6.1. Diz-Küçükkaya R, **Hançer V**, Nalçacı M, İnanç M, Pekçelen Y. 'The role of polymorphism Factor XIII Val34Leu in development of thrombosis in the Antiphospholipid Syndrome. *Turk J Hematol* 2002; 19: 45-46.

7.6.2. Hançer VS, Küçükkaya R, Ergen G, Nalçacı M. İnvestigation of the contribution to Factor XIII polymorphism Val34Leu in patients with coronary artery thrombosis at a young age. *Turk J Hematol* 2003; 20: 25.

7.6.3. Hançer VS, Diz-Küçükkaya R, Nalçacı M. 'The survey of frequency Factor XIII Val34Leu, glycoprotein IBa Kozak and P-selectin glycoprotein ligand 1 polymorfism.' *Turk J Hematol* 2004; 21: 56.

7.6.4. Hançer VS, Diz-Küçükkaya R, Bilge AK, Özben B, Öncül A, Ergen G, Nalçacı M. 'The association between Factor XIII Val34Leu polymorphism and early myocardial infarction in the populations of Turkey.' *Turk Society Cardiology* 2005; 125.

7.6.5. Diz-Küçükkaya R, **Hançer VS**, İnanç M. 'The frequency and clinical significance of platelets Ib alpha-5C / T polymorphism in patients with antiphospholipid syndrome.' *Turk J Hematol* 2006; 23: 40.

7.6.6. Hançer VS, Aktürk F, Güvenç S. 'CTLA-4 A49G polymorphism Autoimmune diseases of the blood and in Chronic Lymphocytic Leukemia.' *Turk J Hematol* 2006;

23:78.

7.6.7. Akber T, **Hançer V**, Diz-Küçükkaya R, Nalçacı M. Assessment of the contribution to the development of thrombosis ,thrombophilic mutations (Factor V LEDs, prothrombin G20210A, Methylene tetrahydrofolate reductase C677T) in chronic myeloproliferative diseases. *Turk J Hematol* 2007; 24: 66.

7.6.8. Yönal İ, Pınarbaşı B, **Hançer VS**, Diz-Küçükkaya R, Kaymakoğlu S. JAK-2 positive to Splanchnic and hepatic venous thrombosis . 34th Proceedings of the National Congress of Hematology 2008; 64.

7.6.9. Hançer VS, Diz-Küçükkaya R, Topal-Sarıkaya A. 'ADAMTS-13 gene mutations in primary antiphospholipid syndrome and transcription analysis.' 34th Proceedings of the National Congress of Hematology 2008; 63.

7.6.10. Hançer VS, Diz-Küçükkaya R, Topal-Sarıkaya A. The characterization of ADAMTS-13 mutations and gene expression in primary antiphospholipid syndrome. 11th National Congress of Medical Biology and Genetics, Book of Abstracts 2009; 168.

7.6.11. Türe-Özdemir F, Yavuz S, **Hançer VS**, Direskeneli H, Yavuz Ş. 'An assessment of the CVD panel (predisposition to cardiovascular disease risk panel) in Behcet's patients. ' *Marmara Medical Journal* 2009; 22: 6

7.6.12. Yönal I, Hindilerden F, **Hançer VS**, Artım-Esen B, Nalçacı M. 'The frequency and clinical effects of platelet membrane glycoprotein polymorphisms in antiphospholipid syndrome .' 36th Proceedings of the National Congress of Hematology 2010; 27-28.

7.6.13. Akpınar TS, **Hançer VS**, Nalçacı M, Diz-Küçükkaya R. MPL W515K / L mutations in myeloproliferative neoplasms. 36th Proceedings of the National Congress of Hematology 2010; 126.

7.6.14. Hançer VS, Köse M, Aktan M, Diz-Küçükkaya R, Yavuz AS, Nalçacı M. , 'Activation-induced cytidin deaminase (AID) mRNA levels in chronic lymphocytic leukemia.'36th Proceedings of the National Congress of Hematology 2010 : 107.

7.6.15. Hançer VS, Varlık T, Büyükdoğan M, Altuğ T, Diz-Küçükkaya R.. The contribution of activation-induced cytidine deaminase to antiphospholipid syndrome at transcriptional level. Proceedings of the National Congress of Hematology 2010;52-53.

7.6.16. Hançer VS, Aktan M, Diz-Küçükkaya R, Yavuz AS, Nalçacı M. 'Overexpression of Fc Mu Receptor (FCMR) Gene in Chronic Lymphocytic Leukemia Patients' 36th Proceedings of the National Congress of Hematology 2010; 23-24.

7.6.17. **Hançer VS**, Demir G, Türkmen İ, Büyükdoğan M, Başsüllü N, Altuğ T, Diz-Küçükkaya R,Bülbül-Doğusoy G. 'Comparison of tests used in the analysis of KRAS mutation.' Turkish Journal of Pathology 2010; 26 : 162-163

7.6.18. Hançer VS, Hindilerden F, Büyükdoğan M Hasbal NB, Arat M, Diz-Küçükkaya R. Whether citidin deaminase (AID) induced with the activation is the cause of somatic hypermutation in the acute myeloblastic leukemia, or not? 37th Proceedings of the National Congress of Hematology 2011; 9-10.

7.6.19. Tekeoğlu S, **Hançer VS**, Nalçacı M, Diz-Küçükkaya R. 'The frequency and the clinic importance of polymorphism beta 2 glycoprotein I Valin247Leu in the Antiphospholipid syndrome' 37th Proceedings of the National Congress of Hematology 2011; 49-50.

7.6.20. Hindilerden F, Hasbal NB, **Hançer VS**, Büyükdoğan M, Arat M, Diz-Küçükkaya R. 'A companied with Acute Premiyelositer leukemia cases of acute ischemic stroke clinic.' 37th Proceedings of the National Congress of Hematology 2011; 71-72.

7.6.21. Hançer VS, Diz-Küçükkaya R, Akagün T, Türkmen A. 'Mutations of heterozygote complement factor H (Q925X) related with atypical hemolytic uremic syndrome: a case report.' 37th Proceedings of the National Congress of Hematology 2011; 137.

7.6.22. Yönal İ, Pınarbaşı B, Hindilerden F, **Hançer VS,** Nalçacı M, Kaymakoğlu S, Diz-Küçükkaya R 'The importance of the JAK2 V617F mutation for diagnosis of Philadelphia negative chronic myeloproliferative disease in the Splanchnic venous thrombosis' ombocytosis'37th Proceedings of the National Congress of Hematology 2011; 164-165.

7.6.23. Hindilerden F, Hasbal NB, **Hançer VS**, Büyükdoğan M, Arat M, Diz-Küçükkaya R. 'A case of Philadelphia-positive chronic myeloid leukemia process severe thrombocytosis' 37th Proceedings of the National Congress of Hematology 2011; 167.

7.6.24. Tekgündüz E, Halhallı S, Velet S, Turgut B, **Hançer VS,** Diz-Küçükkaya R, Demir M. 'The threatment throught plasmapheresis to two pregnant with the case of Thrombotic Thrombocytopenic Purpura' 37th Proceedings of the National Congress of Hematology 2011;188-189.

7.6.25. Turan C, **Hançer VS**, Güvenç S, Hindilerden F, Büyükdoğan M, Arat M, Diz-Küçükkaya R. 'The role of Methylcytosine deoksigenaz 2 (TET2) mutations in the myeloproliferative neoplasms.' 38th Proceedings of the National Congress of Hematology 2012; 28-29.

7.6.26. Hançer VS, Güvenç S, Hindilerden F, Büyükdoğan M, Diz-Küçükkaya R '. 'The study of contribution to Complement pathway mutations in the atypical hemolytic uremic syndrome' 38th Proceedings of the National Congress of Hematology 2012; 34-35.

7.6.27. Hançer VS, Güvenç S, Hindilerden F, Büyükdoğan M, Diz-Küçükkaya R. 'The study of contribution to Complement pathway mutations in the atypical hemolytic uremic syndrome' 10th Proceedings of the National Congress of Medical Genetics 2012; 150.

7.6.28. Hindilerden F, Güvenç S, Hasbal NB, **Hançer VS**, Diz-Küçükkaya R. Özçelik ET, Arat M. Use of tyrosine kinase inhibitors in relapse and rescue treatment after allogeneic stem cell transplantation in Philadelphia positive myeloid neoplasms. 39th Proceedings of the National Congress of Hematology 2013; 79.

7.6.29. Hançer VS, Güvenç S, Hindilerden F, Büyükdoğan M, Diz-Küçükkaya R. Analysis of Complement pathway mutations in Atypical Hemolytic Uremic Syndrome (AHUS). 39th Proceedings of the National Congress of Hematology 2013; 35.

7.6.30. Güvenç S, Uslu N, Arslan A, **Hançer VS,** Hindilerden F, Arat M, Diz-Küçükkaya R. Patients with high-risk thrombophilic mutation: Attention to obesity. 39th Proceedings of the National Congress of Hematology 2013; 270-271.

7.6.31. Pilancı KN, Elbüken F, **Hançer VS,** Büyükdoğan M, Ordu Ç, Okutur K, Köksal Ü, Demir OG, Sağlam S. A case of melanoma with different BRAF p.V600E mutation in primary tumor and metastasis. Proceedings of the13th National Medical Biology and Genetics Congress 2013; 144.

7.6.32. Tokgöz H, Çalışkan Ü. , Diz-Küçükkaya R. ,**Hançer VS**. A case of pediatric essential thrombocythemia characterized by a calreticulin mutation. 41th Proceedings of the National Congress of Hematology 2015; 257.

7.7. Other Publications

7.7.1. Hancer VS. Genetics of Antiphospholipid Syndrome. *Human Genet Embryol* 2011; 1:e103. doi:10.4172/2161-0436.1000e103.

7.7.2. Hancer VS. Acquired Bleeding Disorders and Hereditary Thrombophilia Diagnosis and Common Mistakes. Turkiye Klinikleri J Hem Onc-Special Topics 2012; 5:52-59.

8. Projects

8.1. Contribution of heritable thrombophilia to thrombosis in antiphospholipid syndrome. Research Fund of Istanbul University, 2001. Project No: T-967/19022001, Researcher.

8.2. Contribution of platelet GPIb Kozak polymorphism to thrombosis development in antiphospholipid syndrome. Research Fund of Istanbul University, 2004. Project No: BYP-473/09092004, Researcher.

8.3. Role of PSGL-1 polymorphisms in the etiology of thrombosis. Turkish Academy of Sicence (TUBA), 2004. Proje No:RDK/TUBA GEBIP/2004-15, Researcher.

8.4. Investigation of ADAMTS-13 gene expression in antiphospholipid syndrome and differences in activity and amount of protein in plasma. Research Fund of Istanbul University, 2007. Project No: 1454, Project Manager.

8.5. Transcriptional analysis of activation-induced cytidine deaminase (AID) gene in antiphospholipid syndrome. Research Fund of Istanbul Bilim University, 2010, Project Manager.

8.6. The role of complement factor H polymorphism in assessing the efficacy of intravitreal anti-vascular endothelial growth factor agents used in the treatment of chondroid neovascularization secondary to age-related macular degeneration.. Research Fund of Istanbul Bilim University, 2010, Researcher.

8.7. Transcriptional analysis of T-type calcium channel genes (alpha 1G, alpha 1H, alpha 1I, alpha 1A, alpha 1E) and roles in epilepsy.. Research Fund of Istanbul Bilim University, 2011, Project Manager.

8.8. Association of TNF alpha and SPARC broad polymorphisms with hepatocellular carcinoma in Turkish patients with HBV / HCV infection.. Research Fund of Istanbul Bilim University, 2011, Researcher.

8.9. Transcriptional analysis of neuropeptide Y (NPY) and leptin genes and roles in epilepsy.. Research Fund of Istanbul Bilim University, 2011, Research Fund of Istanbul Bilim University, Researcher.

8.10. P-selectin glycoprotein-1 (PSGL-1) VNTR polymorphism and tissue factor in the thrombocyte contribution to cancer patients.. Research Fund of Istanbul Bilim University, 2011, Research Fund of Istanbul Bilim University, Researcher.

8.11. Investigation of the presence of methylation in the ADAMT-13 gene in Antiphospholipid Syndrome.. Research Fund of Istanbul Bilim University, 2011, Project Manager.

8.12. Investigation of the presence of marker mutation by screening exons of the visual system homeobox (VSX1) gene in individuals with Down syndrome presenting with keratoconus., Research Fund of Istanbul Bilim University 2014. , Project Manager.

8.13. High-purity isolation of nucleic acids and cells from organic materials with robotic system., Tubitak 1511,2015. Researcher.

9. Administrative Services

9.1. Head of the Department, Istanbul Bilim University, Faculty of Medicine, Department of Medical Biology and Genetics, 2015-2016

9.2. Board Member, Istanbul Bilim University Research and training center for Down Syndrome, 2013-2016

9.3. Board Member, Istanbul Bilim University Research and training center for Spina Bifida, 2013-2016.

9.4. Board Member, Istanbul Bilim University, Institute of Health Science, 2013-2016.

9.5. Head of the Department, Istinye University, Faculty of Medicine, Department of Medical Genetics, 2017-present

10. Professional Affiliations

10.1. Medical Biology and Genetics Society

10.2. Member of Turkish Hematology Society

10.3. Member of the Editorial Board of the Human Genetics & Embriology Journal

10.4. Assistant Editor of the Turkish Journal of Hematology

11. Fellowships and Awards

11.1. The Best Study Award with the study titled ‘ The role of factor XIII Val34Leu polymorphism’s in the development of thrombosis within antiphospholipid syndrome ' on 29th National Hematology Congress.November 2002, Antalya,Turkey.

11.2. The Young Participant Award with the study titled ' The survey of contribution of factor XIII Val34Leu polymorphism's in patients with coronary artery thrombosis at a young age' on 30th National Hematology Congress. November 2003,Istanbul,Turkey.

11.3. The Best Study Award with the study titled 'The survey of frequency Factor XIII Val34Leu, P-selectin glycoprotein ligand-1 and glycoprotein Ib Kozak polymorphisms' on the 31th National Hematology Congress. September 2004, Antalya, Turkey.

11.4. Young Participant Award with the study titled 'The survey of frequency Factor XIII Val34Leu, P-selectin glycoprotein ligand-1 and glycoprotein Ib Kozak polymorphisms' on the 31th National Hematology Congress. September 2004, Antalya, Turkey.

11.5. Successful Researcher Award from the Rector of Istanbul University. 2004, Istanbul, Turkey.

11.6. Award of TUBITAK international scientific literature encouragement program, 2005.

11.7. The Best Study Award with the study titled 'CTLA-4 A49G polymorphism in the Autoimmune Blood Disease and Chronic Lymphocytic Leukemia' on the 33th National Hematology Congress. September 2006, Antalya, Turkey.

11.8. The Young Participant Award with the study titled 'ADAMTS-13 gene mutations in primary antiphospholipid syndrome and transcription analysis' on the 34th National Hematology Congress. October 2008, İzmir, Turkey.

11.9. The Best Study Award with the study titled 'The frequency and clinical effects of polymorphisms thrombocyte membrane glycoprotein in the antiphospholipid syndrome ' on the 36th National Hematology Congress. November 2010, Antalya,Turkey.

12. Please fill out the chart below for undergraduate and graduate courses you have given in the last 2 years.

Academic Year	Semester	Course	Weekly Course Hours		Number of Students
			Theoretical	Practical	
2017-2018	**Fall**	Medical Genetics	8	4	73
	Spring	Medical Genetics	5	2	73
2018-2019	**Fall**	Medical Genetics	8	4	107
		Mutation and mutation screening methods (MSc)	2	2	8
	Spring	Medical Genetics	5	2	107